Annual General Meeting of Shareholders in Biacore International AB

Uppsala, Sweden, May 4, 2006. Biacore International AB (SSE: BCOR) announces that today’s Annual General Meeting of shareholders was attended by 23 shareholders, representing 61 percent of the total number of shares and votes in the Company.

The meeting decided, in accordance with the board of directors’ and the president’s proposal, that the non-restricted equity in the Parent Company at the meeting’s disposal, SEK 85,312,000, be used as follows: Dividend to shareholders, SEK 3 per share SEK 29,250,000 To be carried forward as retained earnings SEK 56,062,000 Total SEK 85,312,000 The record date for payment of the dividend was set at May 9, 2006. The meeting re-elected the board members Mr Lars-Göran Andrén, Dr Gordon Edge, Mrs Donna Janson, Mr Ronald Long, Mr Donald R Parfet, Mr Mats Pettersson and Dr Anders Vedin. The unions had appointed Mrs Anna Hansson and Dr Markku Hämäläinen as their representatives on the board and Mrs Anette Persson and Mr Hans Sjöbom as deputies. Mr Donald R Parfet was re-elected chairman of the board. The meeting decided that the directors shall receive a total remuneration of SEK 2,200,000. The chairman of the board shall receive SEK 425,000 and each of the other directors elected at the Meeting SEK 200,000. As additional remuneration for committee work, the chairman of the remuneration committee shall receive SEK 75,000 and each of the other committee members SEK 50,000 for each committee assignment. The meeting decided that remuneration to the auditors shall be paid on approved account. The meeting decided on the principles for appointment of a nomination committee in accordance with the nomination committee’s proposal. The meeting decided in accordance with the board of directors’ proposal to amend the wording of the Articles of Association for the purpose of adapting the Articles of Association to the new Swedish Companies Act which gained force on January 1, 2006, and to make certain editorial adjustments. The meeting decided in accordance with the board of directors’ proposal on the issuance of warrants to subscribe for new shares and approval of employee options as part of a new long term incentive program. The decision mainly involves the following: To secure obligations under the employee options, Biacore shall issue 125,000 warrants to subscribe for new shares in the Company. A wholly-owned subsidiary of Biacore is, with deviation from the shareholders’ preferential right, entitled to subscribe for the warrants. Each warrant entitles the holder to subscribe for one new share in Biacore during the period from May 12, 2006, or the later date when the Swedish Companies Registration Office registers the issue, up to and including June 7, 2011. The subscription price will be equivalent to 115% of the average of the official quotation of the last price paid for the company’s shares listed on the Stockholm Stock Exchange during the period from and including May 5, 2006 up to and including May 11, 2006. Calculated on the share capital and the number of votes after full exercise of outstanding employee options as of December 31, 2005 (including hedging of social security costs of previous programs), the proposed program corresponds to a dilution of approximately 1.2%. Based on the registered share capital and the number of votes, the cumulative dilution from all previous programs of outstanding employee options as of December 31, 2005 (including hedging of social security costs of previous programs) plus the proposed program will correspond to approximately 9.6%. The subsidiary is to utilize the warrants in order to secure obligations pursuant to issued employee options. The employee options will be issued free of charge to employees within the Biacore group. The board of directors will decide on the allotment in each individual case. No more than 20,000 employee options shall be issued to the president/CEO of Biacore International AB, no more than 10,000 employee options each shall be issued to other senior management within the Biacore group and no more than 5,000 employee options each shall be issued to other key employees within the Biacore group. Members of the board who are appointed by the general meeting, and who are not employed by the company, will not receive employee options. Guaranteed allotment shall not occur. The right to exercise employee options will accrue annually by 1/3 per year during 2007-2009. Payment shall be made in an amount for each share corresponding to 115% of the average last price paid for the company’s shares listed on the Stockholm Stock Exchange during the period from and including May 5, 2006 up to and including May 11, 2006. Each employee option allotted will be capped with a maximum appreciation of 250% above the original exercise price. The employee options may be exercised up until May 16, 2011. Social security costs that arise when the employee options are exercised will not be hedged with part of the warrants issued, since the cost for this has not been deemed to outweigh the benefit. The cost of the proposed program includes two parts, which will affect Biacore’s income statement: 1. The cost pertaining to the value of the incentive program, which, according to the Black & Scholes option pricing model and based on certain assumptions, has been estimated to approximately MSEK 4.2 unevenly distributed during three years. 2. Social security costs depending on the share price development. The social security costs are normally calculated on the gap value of the market value of the underlying shares at the time when the employee options are exercised and the strike price for the shares. Assuming a gap value of SEK 100 per employee option and an average rate of social security costs of 28%, the costs will amount to approximately SEK 3.5 million assuming all employee options are exercised. Such costs will be unevenly distributed during the term of the incentive program. - End - For further information, please contact: Donald R. Parfet, Chairman of the board +1 269 217 2008 About Biacore Biacore is a global supplier of analytical systems that improve the productivity of research and development in the life science and pharmaceutical markets. The company's instruments generate unique data on protein interactions, an area of increasing focus in these markets. The data give insights into protein functionality, the role of proteins in normal and diseased states, and the influence of potential drug candidates. Use of Biacore products is well-documented in key areas such as antibody characterization, proteomics, lead optimization and bio-therapeutic development and production. Customers include world renowned life science research centers, all of the leading global pharmaceutical companies and a large number of companies in the emerging biotechnology sector. Biacore is successfully expanding into the food analysis market, providing key manufacturers with ready-to-use solutions for the determination of food quality and safety. The company offers a range of products to meet specific customer needs. All instruments utilize Surface Plasmon Resonance (SPR) technology as the basis for detection and monitoring of protein interactions. Biacore has its own direct sales capability in the world's key markets, United States, Europe, Japan, Australia and a distribution network in Asia-Pacific. The company was created in 1984, is based in Uppsala, Sweden, and is listed on the Stockholm Stock Exchange www.stockholmsborsen.se (SSE:BCOR).